Research and Markets: Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market" report to their offering.

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy and highlights the key opportunities and challenges presented by both business models

On 26th January 2009, Pfizer announced plans to acquire Wyeth for $68 billion. Pfizer's CEO, Jeffrey B Kindler, insisted the deal would be different from the company's earlier mega-deals involving the acquisitions of Pharmacia (2002) and Warner-Lambert (2000) - the acquisition of Wyeth would provide a broad and diversified portfolio, rather than been focused on a single product or cost-cutting. Pfizer's strategy of growing its portfolio through a mega M&A deals follows the 2008 acquisitions of Millennium by Takeda and ImClone by Eli Lilly.

Some key findings from the report

  • Significant industry consolidation will lead to a fundamental shift in the market dynamics across all major product categories.
  • Since the beginning of 2006 a total of seven deals have been agreed with total transaction fees in excess of US$10 billion.
  • It appears likely that the mega-M&A wave started by the 3 deals in Q109 is not yet finished.
  • A handful of major players will follow in the footsteps of Pfizer and enter into major M&A transactions involving a significant step change in market shares and industry consolidation.

Companies Mentioned:

  • Abbott Labs
  • Amgen
  • AstraZeneca
  • Bayer/Schering AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo/Ranbaxy
  • Eisai/MGI Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Merck KGaA/Serono
  • Merck/Schering-Plough
  • Novartis
  • Novo Nordisk
  • Nycomed/Altana Pharma
  • Pfizer
  • Pfizer/Wyeth
  • Roche
  • Roche/Genentech
  • Sanofi-Aventis
  • Schering-Plough
  • Schering-Plough/Organon
  • Takeda
  • Takeda/Millennium
  • Teva
  • Teva/Barr Labs
  • UCB/Schwarz Pharma
  • Wyeth

For more information visit

Source: Spectra Intelligence


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical



Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.